GET DAILY SIGNALSWhy Is Humana (HUM) Stock Up +14.47% Today?
Key Takeaways
- Humana (HUM) shares surged +14.47%, climbing from a prior close of $387.12 to roughly $443.14.
- The primary catalyst was a Medicare Advantage Star Ratings upgrade from the Centers for Medicare & Medicaid Services (CMS).
- Humana's largest contract regained a four-star rating, restoring eligibility for federal quality bonus payments.
- Analyst actions amplified the rally, including a double upgrade at Baird to Outperform with a sharply higher price target.
- The move sharply diverged from peers, with several rival insurers trading lower on the same ratings release.
Opening Summary
HUM, the stock of Humana Inc., one of the largest U.S. health insurers focused on Medicare Advantage plans, staged a powerful rally on Thursday. Shares jumped approximately 14.47%, trading near $443.14 versus a prior session close of $387.12. The advance was driven almost entirely by the overnight release of CMS's 2027 Medicare Advantage Star Ratings, which showed a dramatic recovery in Humana's quality scores and restored its access to lucrative government bonus payments.
CMS Star Ratings Upgrade Fuels the Rally
The decisive driver behind the move was the annual Star Ratings release from the Centers for Medicare & Medicaid Services. Humana's flagship Medicare Advantage contract, covering roughly 2.4 million members, was upgraded to a four-star rating from 3.5 stars. That single step is consequential: plans rated four stars or higher become eligible for quality bonus payments, which flow directly into revenue and margins.
The turnaround was especially meaningful because Humana's ratings had deteriorated sharply in recent years. The share of members in four-star-or-better plans had fallen from about 94% to roughly 20%, costing the company billions in lost bonus revenue. The new ratings mark a reversal of that trend, with Humana reporting that about 95% of its members are now in plans rated four stars or higher. Analysts noted the improvement translated to a materially brighter earnings trajectory for 2028 and beyond.
Analyst Upgrades and Price-Target Hikes
The ratings surprise quickly rippled through the sell side. Baird upgraded HUM to Outperform from Neutral and lifted its price target to $596 from $390, citing the improved Star performance and confidence in the company's earnings power. Oppenheimer also raised its target to $475 from $405, calling Humana the "biggest winner" from the new ratings and estimating the improvement could represent billions of dollars in additional revenue. These upgrades reinforced investor conviction and helped sustain the stock's intraday strength.
Market Context and Trading Activity
The move in HUM was notable for its divergence from the broader managed-care group. While Humana surged, several competitors fell on the same CMS release, with UNH, ELV, CVS, and CNC all trading lower as their own Star Ratings showed relative weakness. CLOV, however, rose as a five-star beneficiary. The gap-up in Humana shares also cleared recent technical resistance, and trading volume was running well above typical levels as investors reacted to the announcement.
What Comes Next for HUM
Looking ahead, investors will monitor how quickly Humana can translate its restored Star Ratings into sustained earnings recovery. The financial benefit of the bonus payments largely materializes in 2028, meaning near-term focus remains on the company's margin execution and membership trends. The Medicare Advantage annual enrollment period opens in mid-October, providing an early read on 2027 membership. Regulatory and legal uncertainty also remains, including litigation around the CMS rating methodology and potential future changes to Medicare reimbursement, both of which could introduce volatility.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are currently among the strongest performers under live market conditions. Tickeron offers hundreds of bots spanning thousands of tickers, with each bot differentiated by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are featured in the Trending AI Robots section. Explore the page to see which automated strategies are adapting best to today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
HUM in upward trend: 10-day moving average moved above 50-day moving average on October 06, 2026
The 10-day moving average for HUM crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on HUM as a result. In 53 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
HUM moved above its 50-day moving average on October 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUM advanced for three days, in 218 of 347 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Bearish Trend Analysis
The 10-day RSI Indicator for HUM moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 22 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Moving Average Convergence Divergence Histogram (MACD) for HUM turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 29 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
HUM broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 5 (best 1 - 100 worst), indicating outstanding price growth. HUM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.591) is normal, around the industry mean (3.380). P/E Ratio (38.811) is within average values for comparable stocks, (124.266). HUM's Projected Growth (PEG Ratio) (1.304) is slightly higher than the industry average of (0.786). Dividend Yield (0.009) settles around the average of (0.009) among similar stocks. P/S Ratio (0.319) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company offers health insurance coverage and related services
Industry ManagedHealthCare
Advertisement